These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32100009)

  • 21. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.
    Shay DK; Chillarige Y; Kelman J; Forshee RA; Foppa IM; Wernecke M; Lu Y; Ferdinands JM; Iyengar A; Fry AM; Worrall C; Izurieta HS
    J Infect Dis; 2017 Feb; 215(4):510-517. PubMed ID: 28329311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis.
    Lee JKH; Lam GKL; Shin T; Kim J; Krishnan A; Greenberg DP; Chit A
    Expert Rev Vaccines; 2018 May; 17(5):435-443. PubMed ID: 29715054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019-2020 Influenza Season in the United States.
    Imran M; Ortiz JR; McLean HQ; Fisher L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac532. PubMed ID: 36320195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15.
    Young-Xu Y; Thornton Snider J; Mahmud SM; Russo EM; Van Aalst R; Thommes EW; Lee JK; Chit A
    Euro Surveill; 2020 May; 25(19):. PubMed ID: 32431290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
    DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
    Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
    Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R
    Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018.
    Bruxvoort KJ; Luo Y; Ackerson B; Tanenbaum HC; Sy LS; Gandhi A; Tseng HF
    Vaccine; 2019 Sep; 37(39):5807-5811. PubMed ID: 31445771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population.
    Paudel M; Mahmud S; Buikema A; Korrer S; Van Voorhis D; Brekke L; Chit A
    Vaccine; 2020 Jun; 38(29):4548-4556. PubMed ID: 32446835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.
    Imran M; Puig-Barbera J; Ortiz JR; Fischer L; O'Brien D; Bonafede M; Mansi JA; Boikos C
    Open Forum Infect Dis; 2022 May; 9(5):ofac167. PubMed ID: 35493131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.
    Dunkle LM; Izikson R; Patriarca P; Goldenthal KL; Muse D; Callahan J; Cox MMJ;
    N Engl J Med; 2017 Jun; 376(25):2427-2436. PubMed ID: 28636855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.
    Pebody R; Whitaker H; Zhao H; Andrews N; Ellis J; Donati M; Zambon M
    Vaccine; 2020 Jan; 38(2):173-179. PubMed ID: 31653528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of influenza vaccine in reducing influenza-associated hospitalizations and deaths among the elderly population; Lazio region, Italy, season 2016-2017.
    Fabiani M; Volpe E; Faraone M; Bella A; Pezzotti P; Chini F
    Expert Rev Vaccines; 2020 May; 19(5):479-489. PubMed ID: 32237925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018-2019 United States Influenza Season.
    Boikos C; Imran M; Nguyen VH; Ducruet T; Sylvester GC; Mansi JA
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab167. PubMed ID: 34327253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
    Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
    Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.
    McLean HQ; Caspard H; Griffin MR; Poehling KA; Gaglani M; Belongia EA; Talbot HK; Peters TR; Murthy K; Ambrose CS
    Vaccine; 2017 May; 35(20):2685-2693. PubMed ID: 28408121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada.
    Nichols MK; Andrew MK; Ye L; Hatchette TF; Ambrose A; Boivin G; Bowie W; Dos Santos G; Elsherif M; Green K; Haguinet F; Katz K; Leblanc J; Loeb M; MacKinnon-Cameron D; McCarthy A; McElhaney JE; McGeer A; Powis J; Richardson D; Semret M; Sharma R; Shinde V; Smyth D; Trottier S; Valiquette L; Webster D; McNeil SA;
    Clin Infect Dis; 2019 Aug; 69(6):970-979. PubMed ID: 30508064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season.
    DeMarcus L; Shoubaki L; Federinko S
    Vaccine; 2019 Jul; 37(30):4015-4021. PubMed ID: 31201055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.